SLC5A2 and type 2 diabetes mellitus: Therefore, we conducted this network meta-analysis based on placebo-controlled cardiorenal outcome trials of SGLT2 inhibitors and finerenone, aiming to assess the relative efficacy of SGLT2 inhibitors versus finerenone on cardiorenal endpoints in patients with T2D and CKD.